Emcure Pharmaceuticals Gains 3.3% as It Completes 100% Acquisition of Zuventus Healthcare

Pune, October 6, 2025: Emcure Pharmaceuticals Limited’s share price is witnessing strong investor demand today, after the company announced that it has acquired the remaining 20.42% stake in Zuventus Healthcare Ltd, making it a wholly owned subsidiary. As of 10:5 AM, the shares of the company were up by 3.31%, or 44.40 points, and were trading at ₹1,384.30. Until now, the shares have traded within a range of ₹1,415.70 and ₹1,348.00. The traded volume stood at 1.43 lakh shares, with a market cap at ₹25,392 crore. The shares have their 52-week high at ₹1,532.95 and their 52-week low at ₹889.

Emcure Pharmaceuticals Limited is an Indian company that is engaged in the manufacturing of pharmaceutical products. The company was established in 1981 and is headquartered in Pune, Maharashtra. The shares of the company are listed on NSE with ticker symbol EMCURE and on BSE with the code 544210.

Emcure Completes 100% Acquisition of Zuventus Healthcare

The increased investor interest in the share price comes after the company announced that it has acquired the remaining 20.42% stake in Zuventus Healthcare Ltd, making it a wholly owned subsidiary. The transaction was executed for a cash consideration of ₹7,249 million, as confirmed in the company’s regulatory filing. The company acquired 4,095,180 equity shares (₹10 each) from individual shareholders. The shares have been credited to Emcure’s demat account after completion of the acquisition process.

With the full acquisition, Emcure will have full control over the operations of Zuventus. It will allow Emcure to benefit from the company’s impressive financial performance. Zuventus recorded turnover growth from ₹9,957.21 million in FY23 to ₹10,798.99 million in FY25, with a PAT of ₹1,347.82 million. Furthermore, Emcure will be able to increase its market presence with the acquisition.

REF: https://nsearchives.nseindia.com/corporate/EMCURE_03102025190322_CompletionofZHLAcquisition.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations